Stock Scorecard



Stock Summary for Syndax Pharmaceuticals Inc (SNDX) - $15.45 as of 9/18/2025 9:10:46 PM EST

Total Score

5 out of 30

Safety Score

35 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for SNDX

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for SNDX

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for SNDX

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for SNDX

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for SNDX (35 out of 100)

Stock Price Rating (Max of 10) 6
Historical Stock Price Rating (Max of 10) 7
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for SNDX

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 ) - Syndax Pharmaceuticals ( NASDAQ:SNDX ) 9/5/2025 8:01:00 PM
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 ) 9/5/2025 8:01:00 PM
Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth - Syndax Pharmaceuticals ( NASDAQ:SNDX ) , Kura Oncology ( NASDAQ:KURA ) 9/4/2025 7:17:00 PM
This HubSpot Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Entergy ( NYSE:ETR ) , AptarGroup ( NYSE:ATR ) 9/4/2025 2:14:00 PM
Wall Street Analysts Believe Syndax ( SNDX ) Could Rally 112.8%: Here's is How to Trade 9/1/2025 1:55:00 PM
Agilent Q3 Earnings Beat Estimates, Revenues Up Y/Y, Shares Rise 8/28/2025 5:59:00 PM
Incyte ( INCY ) Up 9.4% Since Last Earnings Report: Can It Continue? 8/28/2025 3:30:00 PM
Syndax Announces Participation in September Investor Conferences 8/26/2025 11:00:00 AM
Does Syndax ( SNDX ) Have the Potential to Rally 158.36% as Wall Street Analysts Expect? 8/14/2025 1:55:00 PM
Syndax ( SNDX ) Q2 Revenue Jumps 986% 8/4/2025 9:47:00 PM

Financial Details for SNDX

Company Overview

Ticker SNDX
Company Name Syndax Pharmaceuticals Inc
Country USA
Description Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focused on developing innovative therapies for the treatment of cancer. The company's robust pipeline includes novel agents designed to address significant unmet medical needs in various malignancies, leveraging both immuno-oncology and epigenetic modulation strategies. Syndax is committed to advancing its clinical programs to improve outcomes for patients facing challenging cancer diagnoses, positioning itself as a key player in the evolving landscape of cancer therapeutics.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 6/30/2025
Next Earnings Date 11/11/2025

Stock Price History

Last Day Price 15.45
Price 4 Years Ago 21.89
Last Day Price Updated 9/18/2025 9:10:46 PM EST
Last Day Volume 1,923,968
Average Daily Volume 2,196,883
52-Week High 22.50
52-Week Low 8.58
Last Price to 52 Week Low 80.07%

Valuation Measures

Trailing PE N/A
Industry PE 21.79
Sector PE 40.55
5-Year Average PE 4.90
Free Cash Flow Ratio 12.26
Industry Free Cash Flow Ratio 13.37
Sector Free Cash Flow Ratio 29.46
Current Ratio Most Recent Quarter 4.71
Total Cash Per Share 1.26
Book Value Per Share Most Recent Quarter 1.83
Price to Book Ratio 8.08
Industry Price to Book Ratio 29.02
Sector Price to Book Ratio 32.17
Price to Sales Ratio Twelve Trailing Months 16.30
Industry Price to Sales Ratio Twelve Trailing Months 42.45
Sector Price to Sales Ratio Twelve Trailing Months 19.16
Analyst Buy Ratings 10
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 86,142,000
Market Capitalization 1,330,893,900
Institutional Ownership 120.97%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -52.25%
Reported EPS 12 Trailing Months -3.89
Reported EPS Past Year -1.81
Reported EPS Prior Year -3.73
Net Income Twelve Trailing Months -334,988,000
Net Income Past Year -318,758,000
Net Income Prior Year -209,360,000
Quarterly Revenue Growth YOY 985.00%
5-Year Revenue Growth 73.25%
Operating Margin Twelve Trailing Months -182.70%

Balance Sheet

Total Cash Most Recent Quarter 108,636,000
Total Cash Past Year 154,083,000
Total Cash Prior Year 295,394,000
Net Cash Position Most Recent Quarter -222,929,000
Net Cash Position Past Year -177,482,000
Long Term Debt Past Year 331,565,000
Long Term Debt Prior Year 59,894,664
Total Debt Most Recent Quarter 331,565,000
Equity to Debt Ratio Past Year 0.46
Equity to Debt Ratio Most Recent Quarter 0.32
Total Stockholder Equity Past Year 288,124,000
Total Stockholder Equity Prior Year 554,196,000
Total Stockholder Equity Most Recent Quarter 157,424,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -302,667,000
Free Cash Flow Per Share Twelve Trailing Months -3.51
Free Cash Flow Past Year -274,903,000
Free Cash Flow Prior Year -160,601,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 1.04
MACD Signal 1.24
20-Day Bollinger Lower Band 6.07
20-Day Bollinger Middle Band 11.80
20-Day Bollinger Upper Band 17.53
Beta 0.72
RSI 57.83
50-Day SMA 13.89
150-Day SMA 18.51
200-Day SMA 18.61

System

Modified 9/18/2025 10:14:05 AM EST